<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Media S.A. pmcid: 6901432 doi: 10.3389/fmicb.2019.02790 : Microbiology: Original Research" exact="Omeprazole" post="Increases the Efficacy of Acyclovir Against Herpes Simplex Virus"/>
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Omeprazole" post="was shown to improve the anti-cancer effects of the"/>
 <result pre="anti-cancer effects of the nucleoside analogue 5-fluorouracil. Here, we combined" exact="omeprazole" post="with the antiviral nucleoside analogues ribavirin and acyclovir. Omeprazole"/>
 <result pre="5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues" exact="ribavirin" post="and acyclovir. Omeprazole did not affect the antiviral effects"/>
 <result pre="combined omeprazole with the antiviral nucleoside analogues ribavirin and acyclovir." exact="Omeprazole" post="did not affect the antiviral effects of ribavirin in"/>
 <result pre="and acyclovir. Omeprazole did not affect the antiviral effects of" exact="ribavirin" post="in non-toxic concentrations up to 80 μg/mL but increased"/>
 <result pre="and 2 (HSV-1 and -2) replication in a dose-dependent manner." exact="Omeprazole" post="alone reduced HSV-1 and -2 titers [but not HSV-induced"/>
 <result pre="concentrations ≥40 μg/mL. However, it exerted substantially stronger effects on" exact="acyclovir" post="activity and also increased acyclovir activity at lower concentrations"/>
 <result pre="exerted substantially stronger effects on acyclovir activity and also increased" exact="acyclovir" post="activity at lower concentrations that did not directly interfere"/>
 <result pre="lower concentrations that did not directly interfere with HSV replication." exact="Omeprazole" post="80 μg/mL caused a 10.8-fold (Vero cells) and 47.7-fold"/>
 <result pre="10.8-fold (Vero cells) and 47.7-fold (HaCaT cells) decrease of the" exact="acyclovir" post="concentrations that reduced HSV-1-induced CPE formation by 50% (IC50)."/>
 <result pre="reduced HSV-1-induced CPE formation by 50% (IC50). In HSV-2-infected cells," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50 by 7.3- (Vero"/>
 <result pre="50% (IC50). In HSV-2-infected cells, omeprazole 80 μg/mL reduced the" exact="acyclovir" post="IC50 by 7.3- (Vero cells) and 12.9-fold (HaCaT cells)."/>
 <result pre="7.3- (Vero cells) and 12.9-fold (HaCaT cells). In HaCaT cells," exact="omeprazole" post="80 μg/mL reduced the HSV-1 titer in the presence"/>
 <result pre="80 μg/mL reduced the HSV-1 titer in the presence of" exact="acyclovir" post="1 μg/mL by 1.6 × 105-fold and the HSV-2"/>
 <result pre="× 105-fold and the HSV-2 titer in the presence of" exact="acyclovir" post="2 μg/mL by 9.2 × 103-fold. The proton pump"/>
 <result pre="pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased the antiviral effects of" exact="acyclovir" post="in a similar fashion as omeprazole, indicating this to"/>
 <result pre="In conclusion, proton pump inhibitors increase the anti-HSV activity of" exact="acyclovir" post="and are candidates for antiviral therapies in combination with"/>
 <result pre="from severe complications. HSV HSV-1 HSV-2 antiviral therapy antiviral drugs" exact="ribavirin" post="proton pump inhibitors fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
 <result pre="proton pump inhibitors fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Omeprazole" post="and other proton pump inhibitors have been found to"/>
 <result pre="Chemaly et al., 2019). Here, we investigated the effects of" exact="omeprazole" post="on the efficacy of the antiviral nucleoside analogues acyclovir"/>
 <result pre="of omeprazole on the efficacy of the antiviral nucleoside analogues" exact="acyclovir" post="and ribavirin. The guanosine analogue acyclovir and its pro-drug"/>
 <result pre="the antiviral nucleoside analogues acyclovir and ribavirin. The guanosine analogue" exact="acyclovir" post="and its pro-drug valacyclovir are used for the treatment"/>
 <result pre="acyclovir and ribavirin. The guanosine analogue acyclovir and its pro-drug" exact="valacyclovir" post="are used for the treatment of disease caused by"/>
 <result pre="and tri-phosphorylated by cellular kinases. The active tri-phosphorylated forms of" exact="acyclovir" post="and then specifically interferes with the viral DNA polymerase"/>
 <result pre="Boivin, 2016; Chen et al., 2017; Zarrouk et al., 2017)." exact="Ribavirin" post="is a guanosine analogue that has been shown to"/>
 <result pre="influenza viruses and West Nile virus. The mechanisms by which" exact="ribavirin" post="interferes with virus replication are not clear and may"/>
 <result pre="al., 2018; Keppeke et al., 2019). Our findings show that" exact="omeprazole" post="(and other proton pump inhibitors) increase the antiviral activity"/>
 <result pre="(and other proton pump inhibitors) increase the antiviral activity of" exact="acyclovir" post="but not that of ribavirin. Materials and Methods Cell"/>
 <result pre="Kärber, 1931). Drugs Acyclovir was received from GlaxoSmithKline (Munich, Germany)," exact="omeprazole" post="from AstraZeneca (Wedel, Germany), ribavirin from Valeant Pharmaceuticals Germany"/>
 <result pre="received from GlaxoSmithKline (Munich, Germany), omeprazole from AstraZeneca (Wedel, Germany)," exact="ribavirin" post="from Valeant Pharmaceuticals Germany GmbH (Eschborn, Germany), and pantoprazole,"/>
 <result pre="than 0.05 were considered to be significant. Results Effects of" exact="Omeprazole" post="on Cell Viability The effects of omeprazole on the"/>
 <result pre="Results Effects of Omeprazole on Cell Viability The effects of" exact="omeprazole" post="on the viability of the investigated cell lines was"/>
 <result pre="lines was tested in concentrations of up to 160 μg/mL." exact="Omeprazole" post="concentrations of 80 μg/mL and lower did not affect"/>
 <result pre="affect the viability of any of the tested cell lines." exact="Omeprazole" post="160 μg/mL resulted in a reduction of cell viability,"/>
 <result pre="50% (CC50) was not reached (Supplementary Figure S1). Effects of" exact="Omeprazole" post="in Combination With Ribavirin on Cytopathogenic Effect (CPE) Formation"/>
 <result pre="reached (Supplementary Figure S1). Effects of Omeprazole in Combination With" exact="Ribavirin" post="on Cytopathogenic Effect (CPE) Formation in WNV- or Influenza"/>
 <result pre="Effect (CPE) Formation in WNV- or Influenza A H1N1-Infected Cells" exact="Omeprazole" post="80 μg/mL did not alter the effects of ribavirin"/>
 <result pre="Cells Omeprazole 80 μg/mL did not alter the effects of" exact="ribavirin" post="on CPE formation in WNV-infected Vero cells or H1N1-infected"/>
 <result pre="presence of antiviral nucleoside analogues and omeprazole. (A) Effects of" exact="omeprazole" post="(80 μg/mL) on the concentrations of antiviral nucleoside analogues"/>
 <result pre="MDCK cells, and HSV-1- or HSV-2-infected Vero or HaCaT cells." exact="Omeprazole" post="alone did not reduce CPE formation. Numerical values are"/>
 <result pre="values are presented in Supplementary Table S1. (B) Effects of" exact="omeprazole" post="and acyclovir on the expression of virus proteins in"/>
 <result pre="presented in Supplementary Table S1. (B) Effects of omeprazole and" exact="acyclovir" post="on the expression of virus proteins in HSV-1- and"/>
 <result pre="HSV-1- and HSV-2-infected Vero cells. HSV-1-infected cells were treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were"/>
 <result pre="cells. HSV-1-infected cells were treated with omeprazole 80 μg/mL and/or" exact="acyclovir" post="0.31 μg/mL. HSV-2-infected cells were treated with omeprazole 40"/>
 <result pre="μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were treated with" exact="omeprazole" post="40 μg/mL and/or acyclovir 0.6 μg/mL. (C) HSV gB"/>
 <result pre="μg/mL. HSV-2-infected cells were treated with omeprazole 40 μg/mL and/or" exact="acyclovir" post="0.6 μg/mL. (C) HSV gB levels in HSV-1-infected Vero"/>
 <result pre="(C) HSV gB levels in HSV-1-infected Vero cells treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL as determined by"/>
 <result pre="in HSV-1-infected Vero cells treated with omeprazole 80 μg/mL and/or" exact="acyclovir" post="0.31 μg/mL as determined by Western blot 24 h"/>
 <result pre="determined by Western blot 24 h post infection. Effects of" exact="Omeprazole" post="in Combination With Acyclovir on HSV-1 and HSV-2 Replication"/>
 <result pre="spontaneously immortalized human keratinocyte cell line (Boukamp et al., 1988)." exact="Omeprazole" post="on its own did not affect HSV-1- and HSV-2-induced"/>
 <result pre="HSV-2-induced CPE formation (Supplementary Table S1). In the presence of" exact="omeprazole" post="80 μg/mL, however, acyclovir concentrations that reduced CPE formation"/>
 <result pre="Table S1). In the presence of omeprazole 80 μg/mL, however," exact="acyclovir" post="concentrations that reduced CPE formation by 50% (IC50) were"/>
 <result pre="HSV-2-infected Vero cells (Figure 1A and Supplementary Table S1). Further," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50s by 48-fold in"/>
 <result pre="and Supplementary Table S1). Further, omeprazole 80 μg/mL reduced the" exact="acyclovir" post="IC50s by 48-fold in HSV-1-infected HaCaT cells and by"/>
 <result pre="numbers of virus-infected cells after treatment with a combination of" exact="omeprazole" post="and acyclovir compared to either single treatment (Figure 1B)."/>
 <result pre="virus-infected cells after treatment with a combination of omeprazole and" exact="acyclovir" post="compared to either single treatment (Figure 1B). In agreement,"/>
 <result pre="treated with this combination (Figure 1C). Further experiments indicated that" exact="omeprazole" post="reduced acyclovir IC50s in HSV-1- and HSV-2-infected HaCaT cells"/>
 <result pre="this combination (Figure 1C). Further experiments indicated that omeprazole reduced" exact="acyclovir" post="IC50s in HSV-1- and HSV-2-infected HaCaT cells in a"/>
 <result pre="2 and Supplementary Table S2). FIGURE 2 Concentration-dependent effects of" exact="omeprazole" post="on the acyclovir IC50 in HSV-1- or HSV-2-infected HaCaT"/>
 <result pre="Table S2). FIGURE 2 Concentration-dependent effects of omeprazole on the" exact="acyclovir" post="IC50 in HSV-1- or HSV-2-infected HaCaT cells as determined"/>
 <result pre="combination. ∗P &amp;lt; 0.05 relative to nucleoside analogue alone. Although" exact="omeprazole" post="did not affect the HSV-1 and HSV-2 CPEs in"/>
 <result pre="of virus titers in Vero cells showed that 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-1 particles and that"/>
 <result pre="of infectious HSV-1 particles and that 40 and 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-2 particles. In agreement"/>
 <result pre="particles. In agreement with the findings from the CPE assays," exact="omeprazole" post="also strongly increased the anti-HSV-1 and anti-HSV-2 effects of"/>
 <result pre="and anti-HSV-2 effects of acyclovir. Notably, this omeprazole-induced increase of" exact="acyclovir" post="activity was also seen at lower omeprazole concentrations, which"/>
 <result pre="omeprazole-induced increase of acyclovir activity was also seen at lower" exact="omeprazole" post="concentrations, which did not directly reduce virus titers (Figure"/>
 <result pre="virus titers (Figure 3 and Supplementary Table S3). The investigated" exact="omeprazole" post="and acyclovir concentrations did not affect cell viability, neither"/>
 <result pre="(Figure 3 and Supplementary Table S3). The investigated omeprazole and" exact="acyclovir" post="concentrations did not affect cell viability, neither alone not"/>
 <result pre="viability, neither alone not in combination. FIGURE 3 Effect of" exact="acyclovir" post="1 μg/mL (HSV-1) or 2 μg/mL (HSV-2) alone or"/>
 <result pre="or 2 μg/mL (HSV-2) alone or in combination with varying" exact="omeprazole" post="(OME) concentrations (μg/mL) on HSV-1 and HSV-2 titres in"/>
 <result pre="presented in Supplementary Table S3. ∗P &amp;lt; 0.05 relative to" exact="acyclovir" post="alone, #P &amp;lt; 0.05 relative to untreated virus control;"/>
 <result pre="cells. All tested proton pump inhibitors increased the activity of" exact="acyclovir" post="(Figure 4 and Supplementary Table S4), which suggests that"/>
 <result pre="effect. FIGURE 4 Effects of different proton pump inhibitors on" exact="acyclovir" post="activity in HSV-1-infected HaCaT cells as indicated by cytopathogenic"/>
 <result pre="presented in Supplementary Table S4. ∗P &amp;lt; 0.05 relative to" exact="acyclovir" post="alone. Discussion Based on previous investigations that showed that"/>
 <result pre="acyclovir alone. Discussion Based on previous investigations that showed that" exact="omeprazole" post="increases the anti-cancer activity of the nucleoside analog 5-fluorouracil"/>
 <result pre="(Luciani et al., 2004), we here investigated the effects of" exact="omeprazole" post="on the antiviral effects of ribavirin and acyclovir. Omeprazole"/>
 <result pre="investigated the effects of omeprazole on the antiviral effects of" exact="ribavirin" post="and acyclovir. Omeprazole did not modify ribavirin-mediated effects in"/>
 <result pre="of omeprazole on the antiviral effects of ribavirin and acyclovir." exact="Omeprazole" post="did not modify ribavirin-mediated effects in H1N1 influenza A"/>
 <result pre="fashion in Vero and HaCaT cells. It remains unclear why" exact="omeprazole" post="increases the activity of acyclovir but not that of"/>
 <result pre="cells. It remains unclear why omeprazole increases the activity of" exact="acyclovir" post="but not that of ribavirin. Differences between the compounds"/>
 <result pre="acyclovir but not that of ribavirin. Differences between the compounds" exact="acyclovir" post="and ribavirin including their mechanisms of action and/or differences"/>
 <result pre="not that of ribavirin. Differences between the compounds acyclovir and" exact="ribavirin" post="including their mechanisms of action and/or differences between the"/>
 <result pre="viruses may be responsible for this. The mechanism by which" exact="omeprazole" post="enhances the activity of acyclovir seems to differ from"/>
 <result pre="this. The mechanism by which omeprazole enhances the activity of" exact="acyclovir" post="seems to differ from the mechanism by which omeprazole"/>
 <result pre="of acyclovir seems to differ from the mechanism by which" exact="omeprazole" post="increases 5-fluorouracil efficacy, which was shown to be the"/>
 <result pre="lysosomal pH (Luciani et al., 2004). Lysosomotropic drugs such as" exact="chloroquine" post="and ammonium chloride are known to interfere with the"/>
 <result pre="Baines, 2011; Al-Bari, 2017; Salata et al., 2017). In agreement," exact="omeprazole" post="concentrations ≥40 μg/mL reduced HSV-1 and HSV-2 titers. However,"/>
 <result pre="μg/mL reduced HSV-1 and HSV-2 titers. However, the effects of" exact="omeprazole" post="on the anti-HSV activity of acyclovir were more pronounced"/>
 <result pre="However, the effects of omeprazole on the anti-HSV activity of" exact="acyclovir" post="were more pronounced than the direct antiviral effects and"/>
 <result pre="were more pronounced than the direct antiviral effects and lower" exact="omeprazole" post="concentrations, which did not affect HSV-1 and HSV-2 replication,"/>
 <result pre="efficacy of acyclovir. This indicates that the induction of increased" exact="acyclovir" post="activity is not a direct consequence of antiviral activity"/>
 <result pre="is not a direct consequence of antiviral activity exerted by" exact="omeprazole" post="and may be caused by a different mechanism. Moreover,"/>
 <result pre="omeprazole and may be caused by a different mechanism. Moreover," exact="omeprazole" post="pre-treatment was necessary to increase 5-fluorouracil activity (Luciani et"/>
 <result pre="necessary to increase 5-fluorouracil activity (Luciani et al., 2004), but" exact="omeprazole" post="and acyclovir exerted their combined activity when added at"/>
 <result pre="increase 5-fluorouracil activity (Luciani et al., 2004), but omeprazole and" exact="acyclovir" post="exerted their combined activity when added at the same"/>
 <result pre="h post infection. This indicates that the mechanisms by which" exact="omeprazole" post="increases 5-fluorouracil and acyclovir activity differ and that omeprazole"/>
 <result pre="indicates that the mechanisms by which omeprazole increases 5-fluorouracil and" exact="acyclovir" post="activity differ and that omeprazole increases the antiviral activity"/>
 <result pre="which omeprazole increases 5-fluorouracil and acyclovir activity differ and that" exact="omeprazole" post="increases the antiviral activity of acyclovir during the viral"/>
 <result pre="activity differ and that omeprazole increases the antiviral activity of" exact="acyclovir" post="during the viral replication cycle after infection and virus"/>
 <result pre="The proton pump inhibitors pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased" exact="acyclovir" post="activity in a similar manner as omeprazole. Hence, the"/>
 <result pre="omeprazole. Hence, the capacity to increase the antiviral activity of" exact="acyclovir" post="seems to be a drug class effect, which is"/>
 <result pre="on H+/K+ ATPase activity, which may contribute to the increased" exact="acyclovir" post="activity mediated by proton pump inhibitors (Balza et al.,"/>
 <result pre="al., 2016; Nelson et al., 2017; Ghebre, 2018). In addition," exact="omeprazole" post="may inhibit DNA damage repair (Martelli et al., 1998),"/>
 <result pre="the efficacy of acyclovir. Therefore, proton pump inhibitors may increase" exact="acyclovir" post="activity by mechanisms that do not involve the modulation"/>
 <result pre="do not involve the modulation of the lysosomal pH. Since" exact="omeprazole" post="is a clinically well-established drug with a preferable safety"/>
 <result pre="the introduction of topical acyclovir/hydrocortisone combinations (Nguyen et al., 2014)." exact="Omeprazole" post="may not exert general immunosuppressive effects in the same"/>
 <result pre="not exert general immunosuppressive effects in the same way as" exact="hydrocortisone" post="but to more specifically increase acyclovir activity. In immunodeficiency"/>
 <result pre="the same way as hydrocortisone but to more specifically increase" exact="acyclovir" post="activity. In immunodeficiency individuals, HSV-1 and -2 infections are"/>
 <result pre="often associated with more severe disease, and resistance formation to" exact="acyclovir" post="is a severe problem (Piret and Boivin, 2016; Karrasch"/>
 <result pre="context, proton pump inhibitors are promising candidates for combination with" exact="acyclovir" post="or valacyclovir in topical preparations. Further research will have"/>
 <result pre="pump inhibitors are promising candidates for combination with acyclovir or" exact="valacyclovir" post="in topical preparations. Further research will have to show"/>
 <result pre="be feasible in a severe acute disease setting. In conclusion," exact="omeprazole" post="and other proton pump inhibitors substantially enhance the antiviral"/>
 <result pre="other proton pump inhibitors substantially enhance the antiviral effects of" exact="acyclovir" post="in HSV-1- and HSV-2-infected cells. With their known safety"/>
 <result pre="References References Al-BariM. A. A. (2017). Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
 <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance.Curr. Opin. Virol.810–15. 10.1016/j.coviro.2014.04.01124846716 BoukampP.PetrussevskaR. T.BreitkreutzD.HornungJ.MarkhamA.FusenigN. E. (1988). Normal"/>
 <result pre="cells (Vero).J. Virol.2955–961. 4302013 GalliA.MensH.GottweinJ. M.GerstoftJ.BukhJ. (2018). Antiviral effect of" exact="Ribavirin" post="against HCV associated with increased frequency of G-to-A and"/>
 <result pre="und Pharmakologie162480–483. 10.1007/bf01863914 KarraschM.LiermannK.BetzB. B.WagnerS.SchollS.DahmsC.et al. (2018). Rapid acquisition of" exact="acyclovir" post="resistance in an immunodeficient patient with herpes simplex encephalitis.J."/>
 <result pre="Sci.38489–90. 10.1016/j.jns.2017.11.02429249385 KeppekeG. D.CaliseS. J.ChanE. K. L.AndradeL. E. C. (2019)." exact="Ribavirin" post="induces widespread accumulation of IMP dehydrogenase into rods/rings structures"/>
 <result pre="of print]. KohC.LiangT. J. (2014). What is the future of" exact="ribavirin" post="therapy for hepatitis C?Antiviral Res.10434–39. 10.1016/j.antiviral.2014.01.00524468277 KoyamaA. H.UchidaT. (1984)."/>
 <result pre="Natl. Cancer Inst.961702–1713. 10.1093/jnci/djh30515547183 MartelliA.MattioliF.MeretoE.Brambilla CampartG.SiniD.BergamaschiG.et al. (1998). Evaluation of" exact="omeprazole" post="genotoxicity in a battery of in vitro and in"/>
 <result pre="R.DowningC.StiegelK. R. (2014). Recent approval of Xerese in Canada: 5%" exact="acyclovir" post="and 1% hydrocortisone topical cream in the treatment of"/>
 <result pre="Recent approval of Xerese in Canada: 5% acyclovir and 1%" exact="hydrocortisone" post="topical cream in the treatment of herpes labialis.Skin Therapy"/>
</results>
